Ratings by Leerink (Thomas Smith)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/28/2026 | Equillium | EQ | Upgrade | Outperform (Market Perform) |
2.63 (2.93) |
11.41% | Details | |
| 4/13/2026 | Spyre Therapeutics | SYRE | Maintain | Outperform (N/A) |
|
Details | ||
| 4/6/2026 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/2/2026 | Immunovant | IMVT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/31/2026 | Inventiva SA | IVA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2026 | Alumis Inc | ALMS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2026 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/16/2026 | Eledon Pharamceuticals | ELDN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2026 | Evommune Inc | EVMN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/21/2026 | Rapt Therapeutics | RAPT | Downgrade | Market Perform (Outperform) |
35.10 (58.02) |
65.3% | Details | |
| 1/12/2026 | Inventiva SA | IVA | New Coverage | Outperform (N/A) |
4.92 (3.57) |
-27.44% | Details | |
| 1/8/2026 | Abivax | ABVX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2026 | Alumis Inc | ALMS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/8/2025 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 12/1/2025 | Evommune Inc | EVMN | New Coverage | Outperform (N/A) |
20.71 (22.53) |
8.79% | Details | |
| 11/10/2025 | Eledon Pharamceuticals | ELDN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2025 | Madrigal Pharmaceuticals | MDGL | Maintain | Outperform (N/A) |
|
Details | ||
| 10/17/2025 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 10/7/2025 | Abivax | ABVX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/26/2025 | Rapt Therapeutics | RAPT | Upgrade | Outperform (Market Perform) |
24.45 (58.02) |
137.3% | Details | |
| 7/23/2025 | Abivax | ABVX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/4/2025 | Sagimet Biosciences Inc | SGMT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/21/2025 | Tourmaline Bio | TRML | Maintain | Outperform (N/A) |
|
Details | ||
| 3/28/2025 | Equillium | EQ | Downgrade | Market Perform (Outperform) |
0.49 (2.63) |
436.73% | Details | |
| 2/3/2025 | 89bio Inc. | ETNB | Maintain | Outperform (N/A) |
|
Details | ||
| 12/11/2024 | Q32 Bio Inc. | QTTB | Downgrade | Market Perform (Outperform) |
24.41 (12.36) |
-49.37% | Details | |
| 12/2/2024 | Climb Bio | CLYM | New Coverage | Outperform (N/A) |
3.23 (12.18) |
277.09% | Details | |
| 11/12/2024 | Rapt Therapeutics | RAPT | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/4/2024 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 10/4/2024 | Sagimet Biosciences Inc | SGMT | Maintain | Outperform (N/A) |
|
Details | ||
| 10/1/2024 | Sagimet Biosciences Inc | SGMT | Maintain | Outperform (N/A) |
|
Details | ||
| 9/26/2024 | Celldex Therapeutics | CLDX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2024 | Madrigal Pharmaceuticals | MDGL | New Coverage | Outperform (N/A) |
259.45 (512.33) |
97.47% | Details | |
| 7/23/2024 | Alumis Inc | ALMS | New Coverage | Outperform (N/A) |
13.00 (24.57) |
89% | Details | |
| 5/21/2024 | Q32 Bio Inc. | QTTB | New Coverage | Outperform (N/A) |
30.20 (12.36) |
-59.07% | Details | |
| 4/23/2024 | Cartesian Therapeutics | RNAC | New Coverage | Outperform (N/A) |
18.26 (9.79) |
-46.39% | Details | |
| 2/21/2024 | Rapt Therapeutics | RAPT | Downgrade | Market Perform (Outperform) |
6.87 (24.45) |
255.9% | Details | |
| 11/14/2023 | Abivax | ABVX | New Coverage | Outperform (N/A) |
10.50 (99.52) |
847.81% | Details | |
| 8/15/2023 | Galecto | GLTO | Downgrade | Market Perform (Outperform) |
2.34 (21.84) |
833.33% | Details | |
| 5/23/2023 | VectivBio Holding AG | VECT | Downgrade | Market Perform (Outperform) |
11.90 (16.85) |
41.6% | Details | |
| 3/15/2023 | Rapt Therapeutics | RAPT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2023 | Disc Medicine | IRON | New Coverage | Outperform (N/A) |
24.39 (72.13) |
195.74% | Details | |
| 11/30/2022 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/11/2022 | DICE Therapeutics | DICE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/22/2021 | Allakos Inc. | ALLK | Downgrade | Market Perform (Outperform) |
84.39 (0.33) |
-99.61% | Details | |
| 11/18/2021 | Viridian Therapeutic | VRDN | New Coverage | Outperform (N/A) |
19.00 (17.57) |
-7.53% | Details | |
| 11/16/2021 | Landos Biopharma | LABP | Downgrade | Market Perform (Outperform) |
14.01 (22.93) |
63.67% | Details | |
| 9/10/2021 | Celldex Therapeutics | CLDX | New Coverage | Outperform (N/A) |
53.76 (32.69) |
-39.19% | Details | |
| 8/12/2021 | Rapt Therapeutics | RAPT | New Coverage | Outperform (N/A) |
33.07 (58.02) |
75.45% | Details | |
| 5/4/2021 | VectivBio Holding AG | VECT | New Coverage | Outperform (N/A) |
15.21 (16.85) |
10.78% | Details | |
| 4/13/2021 | Connect Biopharma Holdings Ltd | CNTB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/16/2021 | Galecto | GLTO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2021 | Landos Biopharma | LABP | New Coverage | Outperform (N/A) |
13.48 (22.93) |
70.1% | Details | |
| 12/21/2020 | Alaska Air | ALK | New Coverage | Outperform (N/A) |
50.35 (50.38) |
0.06% | Details | |
| 2/25/2020 | Immunovant | IMVT | Maintain | Outperform (N/A) |
|
Details | ||
| 6/18/2019 | Array BioPharma | ARRY | Downgrade | Market Perform (Outperform) |
29.59 (8.59) |
-70.97% | Details | |
| 5/22/2019 | Array BioPharma | ARRY | Maintain | Outperform (N/A) |
|
Details |
